{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T05:50:24Z","timestamp":1771653024322,"version":"3.50.1"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Immune checkpoint inhibitors have demonstrated remarkable efficacy with durable responses in the treatment of various malignancies. This new class of therapeutic agents is associated with a toxicity profile that differs from conventional cytotoxic therapy. The present review is focused on one of these toxicities affecting the respiratory system.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Many types of immune-related adverse events (irAEs) have been identified since the emergence of checkpoint inhibitors including colitis, nephritis, myasthenia gravis-like syndromes, acute interstitial nephritis, pneumonitis, and endocrinopathies. Although pneumonitis is relatively less frequent than other irAEs, this toxicity is by no means inconsequential as it has led to treatment-related deaths during the initial testing phases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Immune-mediated pneumonitis is a potentially serious but relatively infrequent adverse event associated with the use of immune checkpoint inhibitors. IrAEs can be challenging for oncologists who are still unfamiliar with the early presenting symptoms and subsequent management of these toxicities, especially in the context of a rapidly expanding science. A high index of suspicion for pneumonitis must be maintained in patients receiving checkpoint inhibitors and who present new onset respiratory symptoms because this type of toxicity can be severe and potentially fatal.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cco.0000000000000291","type":"journal-article","created":{"date-parts":[[2016,5,3]],"date-time":"2016-05-03T13:29:37Z","timestamp":1462282177000},"page":"269-277","source":"Crossref","is-referenced-by-count":43,"title":["Immune-mediated respiratory adverse events of checkpoint inhibitors"],"prefix":"10.1097","volume":"28","author":[{"given":"Samer","family":"Tabchi","sequence":"first","affiliation":[{"name":"Department of Hematology \u2013 Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Messier","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Normand","family":"Blais","sequence":"additional","affiliation":[{"name":"Department of Hematology \u2013 Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230901","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: back to Virchow?","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet (London, England)"},{"key":"R2-20230901","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1056\/NEJMp1510079","article-title":"Releasing the brakes on cancer immunotherapy","volume":"373","author":"Ribas","year":"2015","journal-title":"New Engl J Med"},{"key":"R3-20230901","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science (New York, NY)"},{"key":"R4-20230901","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"New Engl J Med"},{"key":"R5-20230901","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"New Engl J Med"},{"key":"R6-20230901","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1177\/1060028015586218","article-title":"Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology","volume":"49","author":"Barbee","year":"2015","journal-title":"Annals Pharmacotherapy"},{"key":"R7-20230901","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s40265-014-0305-6","article-title":"Clinical impact of checkpoint inhibitors as novel cancer therapies","volume":"74","author":"Shih","year":"2014","journal-title":"Drugs"},{"key":"R8-20230901","article-title":"Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in nonsmall cell lung cancer","author":"Chow","year":"2013","journal-title":"Am Soc Clin Oncol"},{"key":"R9-20230901","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"R10-20230901","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1200\/JCO.2011.39.3298","article-title":"Pulmonary sarcoid-like granulomatosis induced by ipilimumab","volume":"30","author":"Berthod","year":"2012","journal-title":"J Clin Oncol"},{"key":"R11-20230901","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"key":"R12-20230901","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1084\/jem.20130790","article-title":"RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance","volume":"211","author":"Xiao","year":"2014","journal-title":"J Exp Med"},{"key":"R13-20230901","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nri3790","article-title":"Clinical blockade of PD1 and LAG3 \u2013 potential mechanisms of action","volume":"15","author":"Nguyen","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"R14-20230901","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/656340","article-title":"Programmed death ligand 2 in cancer-induced immune suppression","volume":"2012","author":"Rozali","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"R15-20230901","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJMc1505197","article-title":"Anti-PD-1\u2013related pneumonitis during cancer immunotherapy","volume":"373","author":"Nishino","year":"2015","journal-title":"New Engl J Med"},{"key":"R16-20230901","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","article-title":"Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab","volume":"3","author":"Tirumani","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"R17-20230901","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","article-title":"Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma","volume":"31","author":"Ribas","year":"2013","journal-title":"J Clin Oncol"},{"key":"R18-20230901","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"R19-20230901","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2008-07-168468","article-title":"CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation","volume":"113","author":"Bashey","year":"2009","journal-title":"Blood"},{"key":"R20-20230901","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"New Engl J Med"},{"key":"R21-20230901","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"New Engl J Med"},{"key":"R22-20230901","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"New Engl J Med"},{"issue":"(15_suppl)","key":"R23-20230901","first-page":"8112","article-title":"Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced nonsmall-cell lung cancer (NSCLC): survival and clinical activity by subgroup analysis","volume":"32","author":"Brahmer","year":"2014","journal-title":"ASCO Meeting Abstracts"},{"issue":"(15_suppl)","key":"R24-20230901","first-page":"8020","article-title":"Safety and clinical activity of MK-3475 in previously treated patients (pts) with nonsmall cell lung cancer (NSCLC)","volume":"32","author":"Garon","year":"2014","journal-title":"ASCO Meeting Abstracts"},{"issue":"(18_suppl)","key":"R25-20230901","first-page":"LBA9000","article-title":"Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL)","volume":"32","author":"Ribas","year":"2014","journal-title":"ASCO Meeting Abstracts"},{"key":"R26-20230901","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"R27-20230901","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"New Engl J Med"},{"key":"R28-20230901","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"New Engl J Med"},{"key":"R29-20230901","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"R30-20230901","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"New Engl J Med"},{"key":"R31-20230901","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"New Engl J Med"},{"key":"R32-20230901","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"New Engl J Med"},{"key":"R33-20230901","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced nonsmall-cell lung cancer (KEYNOTE-010): a randomised controlled trial","author":"Herbst","year":"2015","journal-title":"Lancet (London, England)"},{"key":"R34-20230901","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"New Engl J Med"},{"key":"R35-20230901","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"New Engl J Med"},{"key":"R36-20230901","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"R37-20230901","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"New Engl J Med"},{"issue":"(15 Suppl)","key":"R38-20230901","first-page":"128960","article-title":"Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC)","volume":"32","author":"Powles","year":"2014","journal-title":"J Clin Oncology"},{"issue":"(15 Suppl)","key":"R39-20230901","first-page":"134136","article-title":"Preliminary data from a multiarm expansion study of MEDI4736, an anti-PD-L1 antibody","volume":"32","author":"Segal","year":"2014","journal-title":"J Clin Oncol"},{"key":"R41-20230901","doi-asserted-by":"crossref","DOI":"10.1016\/S0959-8049(16)31938-4","article-title":"Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected nonsmall cell lung cancer (NSCLC)","author":"Besse","year":"2015","journal-title":"Eur J Cancer"},{"key":"R42-20230901","doi-asserted-by":"crossref","DOI":"10.1016\/S0959-8049(15)30072-1","article-title":"Atezolizumab monotherapy vs docetaxel in 2L\/3L nonsmall cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR)","author":"Vansteenkiste","year":"2015","journal-title":"Eur J Cancer"},{"key":"R44-20230901","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1164\/rccm.2008-740ST","article-title":"An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients","volume":"183","author":"Limper","year":"2011","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00001622-201607000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T06:22:01Z","timestamp":1693549321000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-201607000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000000291","relation":{},"ISSN":["1040-8746","1531-703X"],"issn-type":[{"value":"1040-8746","type":"print"},{"value":"1531-703X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7]]}}}